MCLEAN, Va. – Oct. 31, 2016 – Northrop Grumman Corporation (NYSE:NOC) has been awarded a contract by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) to provide the maintenance and development of the Medical Dictionary for Regulatory Activities (MedDRA) for organizations around the world. MedDRA is an international medical terminology that is used by the bio/pharmaceutical industry and regulatory authorities to describe adverse events associated with the use of prescription drugs and medical devices. As a global standard, MedDRA is available in 11 languages and is used by more than 4,500 organizations in nearly 100 countries.
“This award highlights our long-standing commitment to the global health community. MedDRA is a well-maintained terminology with excellent services provided to users and a strong tool for global public health," said Amy Caro, vice president, health solutions, Northrop Grumman Technology Services. “Northrop Grumman continues to provide a unique mix of medical expertise, domain knowledge of regulatory requirements and pragmatic maintenance support.”
MedDRA is a classification system for signs, symptoms, diseases, medication errors, product quality issues and other data related to adverse effects of medical products. The use of MedDRA as a standard allows for clear communication between manufacturers and regulatory authorities about the safety of products in development or currently on the market.
Northrop Grumman is a leading global security company providing innovative systems, products and solutions in autonomous systems, cyber, C4ISR, strike, and logistics and modernization to customers worldwide. Please visit www.northropgrumman.com for more information.